FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279118902> ?p ?o ?g. }

• W2279118902 abstract "Background Febrile neutropenia (FN) is a common and potentially fatal complication that can occur during intensive chemotherapy in patients with hematologic disorders. Identification of the cause of FN is very difficult due to the poor diagnostic performance of blood cultures. Thus, the standard of care for FN has been a fever-driven approach with the use of broad-spectrum antibiotics, likely resulting in over-treatment, poor cost-effectiveness, and induction of drug-resistance in bacteria. A novel diagnostic method is needed to improve these problems. CD14, one of the surface markers in monocytes/macrophages, is a lipopolysaccharide-binding protein complex receptor. Some recent studies reported that a fragment released into the blood—soluble CD14-subtype (sCD14-ST)—is promising as a new diagnostic biomarker of infection, especially sepsis (Endo S, et al. J Infect Chemother. 2012;18:891-7). However, the utility of this test in FN is unknown. Methods We prospectively examined the diagnostic value of serum sCD14-ST in patients with hematological disorders who developed FN after chemotherapy or hematopoietic cell transplantation between November 2010 and February 2012. Neutropenia was defined as a neutrophil count of less than 500/μL or less than 1,000/μL with an expected decline to less than 500/μL. Fever was defined as an axillary temperature ≥ 37.5 °C based on a single measurement. Serum was collected within the first 72 hours after the onset of FN in all episodes. During some episodes, serum was collected as a control at the onset of fever, or before chemotherapy when the subjects were afebrile, in accordance with the protocol. Serum sCD14-ST was measured by the two-step enzyme-linked immunosorbent assay using recombinant sCD14-ST as the standards (Yaegashi Y, et al. J Infect Chemother. 2005;11:234-8). Patients with FN were classified into the following four groups: fever of unknown origin, local infection, bacteremia without hypotension, or septic shock. Results A total of 43 patients were eligible and 75 febrile episodes were evaluable. The median age of the patients (44% were male) was 45 years (range: 16–65). Seventy-five blood samples were collected within 72 hours after onset of fever (31 from 0–24 hours, 34 from 24–48 hours, and 10 from 48–72 hours), 12 while afebrile before chemotherapy, and 25 at the onset of fever. The corresponding serum sCD14-ST measurements were termed sCD14-ST<72hr, sCD14-STcon, and sCD14-STonset, respectively. The underlying diseases included acute leukemia (56%), myelodysplastic syndrome (9%), non-Hodgkin’s lymphoma (16%) and others (19%). The median neutrophil count at study enrollment was 67/μL (range 0 to 962). The types of treatment prior to study entry included 49 (65%) chemotherapies, one (1%) autologous hematopoietic cell transplant, and 18 (24%) allogeneic hematopoietic cell transplants. The mean sCD14-STonset value (790 pg/ml, range: 364–1582, n=25) was significantly higher than that for sCD14-STcon (436 pg/ml, range: 262–846, n=12) [unpaired t-test, P<0.001]. In 12 patients with control data, sCD14-ST<72hr was significantly higher than sCD14-STcon (paired t-test, P<0.001). In 25 patients with onset data, sCD14-ST<72hr was significantly higher than sCD14-STonset (paired t-test, P<0.047). The median sCD14-ST<72hrwith fever of unknown origin (n=31), local infection (n=27), bacteremia without hypotension (n=9), septic shock (n=5) and others (n=3) was 680 (314–1986) pg/ml, 763 (348–2615), 782 (482–1550), 1359 (493–2115), and 738 (387–1402), respectively. Conclusion Serum levels of sCD14-ST may be a sensitive indicator of the development of FN. Within 72 hours of the onset of FN, serum levels of sCD14-ST appeared to increase. In addition, sCD14-ST might be a useful marker in detecting potentially lethal septic shock. Further prospective research in a large cohort is warranted to determine not only the diagnostic performance of this test but also its clinical utility as a tool for guiding antibiotic use, including the administration, timing and completion of these drugs in FN. Disclosures: Nakamae: Mochida Pharmaceutical Co., LTD.: Research Funding." @default.
• W2279118902 created "2016-06-24" @default.
• W2279118902 creator A5001816724 @default.
• W2279118902 creator A5008247733 @default.
• W2279118902 creator A5052683455 @default.
• W2279118902 creator A5054464446 @default.
• W2279118902 creator A5076570353 @default.
• W2279118902 creator A5079519158 @default.
• W2279118902 creator A5083093358 @default.
• W2279118902 date "2013-11-15" @default.
• W2279118902 modified "2023-09-27" @default.
• W2279118902 title "Diagnostic Value Of Serum Level Of Soluble CD14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders" @default.
• W2279118902 doi "https://doi.org/10.1182/blood.v122.21.4718.4718" @default.
• W2279118902 hasPublicationYear "2013" @default.
• W2279118902 type Work @default.
• W2279118902 sameAs 2279118902 @default.
• W2279118902 citedByCount "0" @default.
• W2279118902 crossrefType "journal-article" @default.
• W2279118902 hasAuthorship W2279118902A5001816724 @default.
• W2279118902 hasAuthorship W2279118902A5008247733 @default.
• W2279118902 hasAuthorship W2279118902A5052683455 @default.
• W2279118902 hasAuthorship W2279118902A5054464446 @default.
• W2279118902 hasAuthorship W2279118902A5076570353 @default.
• W2279118902 hasAuthorship W2279118902A5079519158 @default.
• W2279118902 hasAuthorship W2279118902A5083093358 @default.
• W2279118902 hasConcept C126322002 @default.
• W2279118902 hasConcept C170493617 @default.
• W2279118902 hasConcept C203014093 @default.
• W2279118902 hasConcept C2776694085 @default.
• W2279118902 hasConcept C2777063308 @default.
• W2279118902 hasConcept C2777408962 @default.
• W2279118902 hasConcept C2778384902 @default.
• W2279118902 hasConcept C2778513237 @default.
• W2279118902 hasConcept C2778850193 @default.
• W2279118902 hasConcept C2779310458 @default.
• W2279118902 hasConcept C2781197716 @default.
• W2279118902 hasConcept C2911091166 @default.
• W2279118902 hasConcept C501593827 @default.
• W2279118902 hasConcept C55493867 @default.
• W2279118902 hasConcept C71924100 @default.
• W2279118902 hasConcept C74133956 @default.
• W2279118902 hasConcept C86803240 @default.
• W2279118902 hasConcept C89423630 @default.
• W2279118902 hasConcept C90924648 @default.
• W2279118902 hasConceptScore W2279118902C126322002 @default.
• W2279118902 hasConceptScore W2279118902C170493617 @default.
• W2279118902 hasConceptScore W2279118902C203014093 @default.
• W2279118902 hasConceptScore W2279118902C2776694085 @default.
• W2279118902 hasConceptScore W2279118902C2777063308 @default.
• W2279118902 hasConceptScore W2279118902C2777408962 @default.
• W2279118902 hasConceptScore W2279118902C2778384902 @default.
• W2279118902 hasConceptScore W2279118902C2778513237 @default.
• W2279118902 hasConceptScore W2279118902C2778850193 @default.
• W2279118902 hasConceptScore W2279118902C2779310458 @default.
• W2279118902 hasConceptScore W2279118902C2781197716 @default.
• W2279118902 hasConceptScore W2279118902C2911091166 @default.
• W2279118902 hasConceptScore W2279118902C501593827 @default.
• W2279118902 hasConceptScore W2279118902C55493867 @default.
• W2279118902 hasConceptScore W2279118902C71924100 @default.
• W2279118902 hasConceptScore W2279118902C74133956 @default.
• W2279118902 hasConceptScore W2279118902C86803240 @default.
• W2279118902 hasConceptScore W2279118902C89423630 @default.
• W2279118902 hasConceptScore W2279118902C90924648 @default.
• W2279118902 hasLocation W22791189021 @default.
• W2279118902 hasOpenAccess W2279118902 @default.
• W2279118902 hasPrimaryLocation W22791189021 @default.
• W2279118902 hasRelatedWork W1991730860 @default.
• W2279118902 hasRelatedWork W2018261737 @default.
• W2279118902 hasRelatedWork W2036731487 @default.
• W2279118902 hasRelatedWork W2136120794 @default.
• W2279118902 hasRelatedWork W2148347227 @default.
• W2279118902 hasRelatedWork W2149585140 @default.
• W2279118902 hasRelatedWork W2358721831 @default.
• W2279118902 hasRelatedWork W2387509942 @default.
• W2279118902 hasRelatedWork W2403426633 @default.
• W2279118902 hasRelatedWork W2411808922 @default.
• W2279118902 hasRelatedWork W2418143941 @default.
• W2279118902 hasRelatedWork W2555523713 @default.
• W2279118902 hasRelatedWork W2570771899 @default.
• W2279118902 hasRelatedWork W2585097528 @default.
• W2279118902 hasRelatedWork W2619603312 @default.
• W2279118902 hasRelatedWork W3022554834 @default.
• W2279118902 hasRelatedWork W3083450098 @default.
• W2279118902 hasRelatedWork W3114196093 @default.
• W2279118902 hasRelatedWork W3137949568 @default.
• W2279118902 hasRelatedWork W46923943 @default.
• W2279118902 isParatext "false" @default.
• W2279118902 isRetracted "false" @default.
• W2279118902 magId "2279118902" @default.
• W2279118902 workType "article" @default.